MedTrace Logo

Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer

NCT01501630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2015-10-14

No results posted yet for this study

Summary

Compare PET/CT and MRI for the early detection of bone metastases of prostate cancer: diagnostic performance and impact on the patient management.Determine the lowest cost strategy according to the precise clinical circumstances.

Conditions

Interventions

DEVICE

performance of PET/CT and whole-body MRI

For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Jean-Noël TALBOT, MD,PhD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501630 on ClinicalTrials.gov